Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α

Journal of Urology

Volumn 185, Issue 1, 2011, Pages 67-71

  Rosevear, Henry M ^a   Lightfoot, Andrew J ^a   Nepple, Kenneth G ^a   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

BCG vaccine; Interferon alfa 2b; Prognosis; Urinary bladder; Urinary bladder neoplasms

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE;

ADULT; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; NONMUSCLE INVASIVE BLADDER CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SPAIN; SYSTEMATIC REVIEW;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 78649981794     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.08.083     Document Type: Article

References (22)

1. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303
2. M.C. Hall, S.S. Chang, and G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
3. H.B. Grossman, M.A. O'Donnell, and M.S. Cookson Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer Rev Urol 10 2008 281
4. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124
5. R.J. Sylvester, A.P. van derMeijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466
6. J. Fernandez-Gomez, R. Madero, and E. Solsona Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model J Urol 182 2009 2195
7. A.M. Kamat Editorial comment: predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated With bacillus Calmette-Guerin: the CUETO scoring model J Urol 182 2009 2203
8. F.N. Joudi, B.J. Smith, and M.A. O'Donnell Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urol Oncol 24 2006 344
9. M.A. O'Donnell Optimizing BCG therapy Urol Oncol 27 2009 325
10. F. Saint, J.J. Patard, and P. Maille Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer J Urol 167 2002 364
11. F.N. Joudi, B.J. Smith, and M.A. O'Donnell The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy J Urol 175 2006 1634
12. J.A. Martinez-Pineiro, N. Flores, and S. Isorna Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer BJU Int 89 2002 671
13. D.L. Lamm BCG immunotherapy for transitional-cell carcinoma in situ of the bladder Oncology (Williston Park) 9 1995 947
14. M. Brake, H. Loertzer, and R. Horsch Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin J Urol 163 2000 1697
15. S.A. Boorjian, F. Zhu, and H.W. Herr The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder BJU Int 106 2010 357
16. Rosevear HM, Lightfoot AJ and O'Donnell MA: Cancer recurrence disparities among racial and gender groups with non-muscle invasive bladder cancer (NMIBC) after intravesical bacillus Calmette-Guerin (BCG) and interferon alpha-2B therapy. Presented at annual meeting of Society for Urologic Oncology, Washington, D.C., December 810, 2009.
17. R.J. Sylvester, W. Oosterlinck, and A.P. van derMeijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186
18. K.G. Nepple, and M.A. O'Donnell The optimal management of T1 high-grade bladder cancer Can Urol Assoc J 3 2009 S188
19. H.W. Herr Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome J Urol 163 2000 60
20. N.M. Streeper, C.M. Simons, and B.R. Konety The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer BJU Int 103 2009 475
21. V. Margulis, Y. Lotan, and P.I. Karakiewicz Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer J Natl Cancer Inst 101 2009 114
22. D.K. Ahirwar, A. Mandhani, and A. Dharaskar Association of tumour necrosis factor-α gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy BJU Int 104 2009 867